As a low-molecular-weight, ATP-competitive kinase inhibitor, BI6727 effectively inhibits PLK1, PLK2, and PLK3 and has shown promising effects in various xenograft models and patients with acute myeloid leukemia (AML) (Gjertsen and Schöffski, 2015). The gene discussed is PLK3; the disease is acute myeloid leukemia.